A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial.

Authors
Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2011
This article has no abstract
Epistemonikos ID: 5e40743a3363a96219297c7183850e2f22d95783
First added on: Feb 04, 2025